Finally, they’ve woken up and smelled the coffee! Obesity is not the issue, metabolic health is.
But there are three other markers that are important: fasting insulin, uric acid, and ALT.
-Dr. Robert Lustig
Endocrine Daily Briefing – From the Endocrine Society
Endocrine Society Issues New Clinical Practice Guideline To Identify People At Metabolic Risk
Medscape (7/31, Busko, Subscription Publication) reports, “By screening for five simple markers – waist size, blood pressure, HDL cholesterol, triglycerides, and glucose/HbA1C – during office visits, clinicians could identify high-risk adults who need to improve their lifestyle to prevent cardiovascular disease or type 2 diabetes [T2D],” experts recommend in a “new clinical practice guideline – ‘Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk’ – issued by the Endocrine Society and published online July 31 in the Journal of Clinical Endocrinology and Metabolism.” Included in the new guideline is “the American Heart Association/American College of Cardiology Pooled Cohort Equation to calculate 10-year risk for atherosclerotic disease.”
Endocrine Today (7/31, Schaffer) reports the guideline states, “The Endocrine Society has recognized the importance of identifying individuals who are at metabolic risk so that efforts can be instituted to prevent both [atherosclerotic] CVD and [type 2 diabetes].” In particular, the guideline “addresses individuals with components of metabolic syndrome who do not yet have diagnosed atherosclerotic CVD or type 2 diabetes and the steps that can be taken to prevent these two diseases.” In addition, it “focuses on behavioral, nutritional and medical management.”
According to Endocrine News (7/31, Seaborg), “the original Endocrine Society guideline on this topic was published in 2008.” This revision, however, “takes a fresh look at metabolic risk and presents recommendations which reflect more recent trial data on blood pressure and lipids,” prioritizing “lifestyle and behavioral interventions” while discussing “new medical treatment options.” Even though “the guideline is targeted towards adults aged 40 to 75,” it “can be used to guide patients outside of this age range as well.”